A 30 Day International, Randomized, Parallel-group, Double-blind, Placebo-controlled Phase IV Study to Evaluate Efficacy and Safety of Pre-hospital vs. In-hospital Initiation of Ticagrelor Therapy in STEMI Patients Planned for PCI.

Trial Profile

A 30 Day International, Randomized, Parallel-group, Double-blind, Placebo-controlled Phase IV Study to Evaluate Efficacy and Safety of Pre-hospital vs. In-hospital Initiation of Ticagrelor Therapy in STEMI Patients Planned for PCI.

Completed
Phase of Trial: Phase IV

Latest Information Update: 30 Aug 2017

At a glance

  • Drugs Ticagrelor (Primary)
  • Indications Myocardial infarction
  • Focus Therapeutic Use
  • Acronyms ATLANTIC
  • Sponsors AstraZeneca
  • Most Recent Events

    • 30 Aug 2017 Results (n=1449) assessing association between peri-procedural anticoagulants and clinical outcomes, presented at the ESC Congress 2017: Annual Congress of the European Society of Cardiology.
    • 30 Aug 2017 Results of a sub group analysis from elderly patients presented at the ESC Congress 2017: Annual Congress of the European Society of Cardiology
    • 30 Aug 2017 Results of subanalysis evaluating predictors of complete ST-segment resolution presented at the ESC Congress 2017: Annual Congress of the European Society of Cardiology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top